Redko Labs research notes · October 13, 2026
Why this field deserves attention
The Berkeley–UCSF Bakar Computational Biomedicine Initiative connects AI, computing, and experiments. This is a strong research signal, while commercial demand still needs to be established workflow by workflow.
One company idea to explore
An evidence workspace for drug-repurposing hypotheses that links each claim to its source, identifies conflicting results, and produces a reviewable experimental brief for a scientist.
A possible first customer
Translational research groups and small biotech teams with a specific disease area and an existing experimental process.
The first experiment
Choose one nonconfidential research question. Have domain experts score evidence completeness, source accuracy, and time saved against their current review process. Seek a scoped, paid research pilot only after demonstrating value.
What a founding team might bring
Bioinformatics, computational biology, chemistry, pharmacology, machine learning, and experimental design.
What must be resolved
Hypothesis generation is not proof of efficacy. University IP, data access, wet-lab validation, and clinical development require separate rights, partners, budgets, and approvals.
This concept is a starting hypothesis from Redko Labs. Bring a different idea, challenge the assumptions, or apply without an idea. The work begins with evidence.
Bring the question.
Build the evidence.
Apply on a rolling basis, with an idea, a company, or the ambition to find your starting point.
Sources and research communities
Universities and organizations are independent of Redko Labs. Their inclusion describes public research activity, not a partnership, endorsement, facility entitlement, or recruitment agreement.
See how the curriculum supports this work